Home>Topics>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR GSK

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Is GlaxoSmithKline A Solid Long-Term Investment?

      Headlines

      Fri, 29 Aug 2014

      as the healthcare sector. However, GlaxoSmithKline (NYSE: GSK ) has been suffering due to some issues in China and poor performance ..... climb up again due to recent FDA drug approvals. Moreover, GSK 's deal with Novartis (NYSE: NVS ) has improved the cash position

    2. AbbVie: Growth Story Or Patent Expiration Nightmare?

      Headlines

      Thu, 28 Aug 2014

      publicly traded drug manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter sales from its

    3. Ebola cases accelerating

      Headlines

      Thu, 28 Aug 2014

      Ebola Vaccine in Preclinicals; BioCryst Pharmaceuticals (NASDAQ: BCRX ): BCX4430 in Preclinicals; GlaxoSmithKline (NYSE: GSK ): Ebola Vaccine in Preclinicals; Nanoviricides (NYSEMKT: NNVC ): NV-INF-1 in Preclinicals; Inovio Pharmaceuticals

    4. UPDATE 1-Ebola vaccine from GSK fast-tracked into clinical trials

      Headlines

      Thu, 28 Aug 2014

      * Trials to vaccinate healthy volunteers from mid-September

    5. Wall Street Breakfast: Telefonica, Telecom Italia In Bidding War For Vivendi's GVT

      Headlines

      Thu, 28 Aug 2014

      By Wall Street Breakfast : Economy In a grudging first step towards opening its state-dominated oil sector, China has granted a crude import license to non-state-owned Guanghui Energy. China's Ministry of Commerce stopped short of truly opening the market, since the new license does not actively ...

    6. GSK Ebola vaccine fast-tracked into U.S., UK and African trials

      Headlines

      Thu, 28 Aug 2014

      LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.

    7. Glaxo's ebola vaccine to begin human clinical trials shortly

      Headlines

      Thu, 28 Aug 2014

      announcement by U.S. health officials today will state that a human study for the Ebola vaccine made by GlaxoSmithKline (NYSE: GSK ) will begin within a couple of weeks instead of later this year as the company originally estimated. Glaxo's vaccine contains

    8. Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

      Headlines

      Wed, 27 Aug 2014

      NEW YORK, Aug 27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the plans.

    9. Tekmira +4% on takeover rumors; Shire, Glaxo said to have interest

      Headlines

      Wed, 27 Aug 2014

      the deadly ebola virus. Rumors suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share on TKMR. Post your

    10. Growth Prospects Remain Strong For Pfizer

      Headlines

      Wed, 27 Aug 2014

      By IAEResearch : The healthcare sector has been performing well over the last few months - in fact, most of the BioPharma companies have outperformed most of the sectors and the overall market itself. However, some of the major players have not been able to show the same price movement - Pfizer ...

    « Prev12345Next »
    Content Partners